Working… Menu

Personalized Oncogenomics (POG) Program of British Columbia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02155621
Recruitment Status : Recruiting
First Posted : June 4, 2014
Last Update Posted : October 30, 2015
BC Cancer Foundation
Information provided by (Responsible Party):
British Columbia Cancer Agency

Brief Summary:
The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy. The investigators will use full genome sequencing to try to identify cancer "drivers" and corresponding drugs that may inhibit these pathways.

Condition or disease Intervention/treatment Phase
Metastatic Cancers Advanced Cancers Cancers That Cannot be Treated With Curative Intent Genetic: Genome sequencing Not Applicable

Detailed Description:

Carcinogenesis is an immensely complex process such that even within a histologic cancer subtype - for example adenocarcinoma of the lung or breast - there is significant variability in cancer behaviour and response to therapy. Analyses of individual patients demonstrate unique molecular signatures for every cancer examined. Frequently, multiple different pathways are involved in disease growth and progression and the dominant process varies from person to person and perhaps even within different sites of disease within one person. As well these variations evolve in response to treatment.

Recognizing genetic aberrations that promote disease facilitates targeted treatment; this has been demonstrated in several small subgroups of cancers in which specific genetic mutations or translocations have been successfully treated with targeted chemotherapy agents. With many recognized mutations and aberrations, personalized evaluation of the genetic signature encoded in DNA and RNA may provide important diagnostic information and potentially enable directed therapy to the appropriate oncologic pathway thereby providing information to help guide chemotherapy choices

Our initial pilot project demonstrated the feasibility of this approach at our institution (with 100 patients). We now know it is possible to identify and consent patients, sequence the genome and transcriptome, analyze and report abnormalities, and identify potential actionable targets in a clinically relevant time frame.

The overarching theme of this POG Program is to create a comprehensive cataloguing of somatic cancer mutations and cellular pathway abnormalities that could generate profound insights into genetic patterns that underlie particular cancer phenotypes, and provide valuable prognostic and predictive information.

Eligible subjects will have several samples analyzed: a fresh tumour biopsy (typically 5 cores are required), a blood sample for normal comparison and archival tumours when available. Comprehensive DNA and RNA sequencing is performed followed by an in-depth bioinformatic analysis to identify somatic mutations, gene expression changes or other abnormalities that might be cancer "drivers" or provide actionable (diagnostic) or druggable targets. The POG team meets every week to discuss the detailed genomic reports for patients, consider additional validation tests when necessary, and debate research questions. The clinicians (typically 5 - 10) come to a consensus on what systemic therapies might be appropriate based on these results. Whenever possible subjects are matched to clinical trials.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5000 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Personalized Oncogenomics (POG) Program of British Columbia: Utilization of Genomic Analysis to Better Understand Tumour Heterogeneity and Evolution
Study Start Date : July 2014
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2025

Arm Intervention/treatment
Experimental: Genome Sequencing
There is only one arm to this study.
Genetic: Genome sequencing
Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis

Primary Outcome Measures :
  1. Influence of genomic data on clinical decision-making [ Time Frame: 5 years ]
    This outcome will allow us to study how often in-depth genomic data impacts on clinical decision-making in a general oncology population. It will help describe how useful or important this sort of data is in daily practice.

  2. Cataloging of cancer genomes [ Time Frame: 5 years ]
    Accumulation of genomic information linked to treatment/outcome data will greatly enhance our knowledge and understanding of cancers and response to treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1. Patients must have histologically or cytologically confirmed diagnosis of cancer; if this is not available but metastatic cancer is virtually certain because of the clinical and radiographic presentation then a POG program biopsy could be done concurrently with a diagnostic biopsy to minimize invasive testing for patients. If the biopsy turned out not to be cancer then the POG analysis may be cancelled.

    2. This cancer must be incurable, as defined by their treating oncologist (generally due to advanced stage).

    3. Patients must agree to provide archival tissue and agree to undergo at least one study specific biopsy at baseline and a blood test for genomic analysis. All subjects will also have a biopsy and blood samples at progression if it could be done safely.

    4. ECOG PS 0 or 1.

    5. Patients may have previously received one line of palliative systemic therapy and/or palliative radiation therapy as needed. In addition, hormone therapy or one line of biologically targeted therapy (such as EGFR inhibitors, BRAF inhibitors, VEGF inhibitors) is permitted and would not count as a line of therapy. Such that a patient could have one line of systemic therapy and one line of hormone or targeted therapy and still be potentially eligible. If the targeted therapy is given concurrently with the systemic chemotherapy that would count as one line of treatment.

    6. Age > 18 years of age.

    7. Patient consent must be obtained according to the BCCA requirements.

    8. Patients must be accessible for follow-up and must be registered at the BCCA. The intention of this program is to serve the population of B.C. such that it is only open to patients currently living and receiving treatment in BC. The ability to track subsequent treatments and outcomes is essential.

    9. Estimated life expectancy of > 6 months.

Exclusion Criteria:

  • 1. Unable or unwilling to undergo tumour biopsy(s) and/or blood/skin samples for normal DNA.

    2. Significant medical condition that in the opinion of the treating or consenting oncologist renders the subject not suitable for participation.

    3. Unwilling or unable to provide treatment and outcome follow up information to the BCCA investigators.

    4. Patients not currently living in and receiving treatment in BC.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02155621

Layout table for location information
Canada, British Columbia
BC Cancer Agency Recruiting
Vancouver, British Columbia, Canada, V5Z 4E6
Contact: Janessa J Laskin, MD   
Principal Investigator: Janessa J Laskin, MD, FRCPC         
Principal Investigator: Marco Marra, PhD         
Sponsors and Collaborators
British Columbia Cancer Agency
BC Cancer Foundation

Publications automatically indexed to this study by Identifier (NCT Number):

Layout table for additonal information
Responsible Party: British Columbia Cancer Agency Identifier: NCT02155621     History of Changes
Other Study ID Numbers: POG 2.0
First Posted: June 4, 2014    Key Record Dates
Last Update Posted: October 30, 2015
Last Verified: October 2015
Keywords provided by British Columbia Cancer Agency:
cancer genomics
precision medicine
metastatic cancer
clinical decision-making
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes